Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Newsroom

  •   Email
  •   Print
  •   Share
  • Dana-Farber Blog

    • Insight Blog screenshot Insight features the latest in cancer care and research news from Dana-Farber.
    • Read the blog 
  • Dana-Farber Facts

    • cover of the Dana-Farber 2017 Facts brochureFind statistics on Dana-Farber's patient care, fundraising initiatives and achievements, and phone numbers for patients and families.
    • View Dana-Farber Facts
  • More than Courage

    • More than Courage coverLearn more about Dana-Farber and the Jimmy Fund's courageous care, innovation, and commitment to beating cancer.
    • View More than Courage
  • The Cancer Treatment Revolution

    • The Cancer Treatment Revolution book cover Dr. David Nathan, acclaimed pediatric hematologist and Dana-Farber's president from 1995 – 2000, recounts that history's triumphs and struggles in his book, The Cancer Treatment Revolution.
     

Dana-Farber Spotlight

Sign up to receive Dana-Farber Spotlight, our email newsletter.
View the current issue
Subscribe now
Unsubscribe from mailings

Media Contacts

Ellen Berlin
Director of Media Relations
617-632-4090
ellen_berlin@dfci.harvard.edu 

Molly McHale
Associate Director of Media Relations
617-632-4090
molly_mchale@dfci.harvard.edu 

 

Top News Releases

Toni Choueiri, MD
Peter Sicinski, MD, PhD
  • June 12, 2017
  • Already-promising cancer drug may have wider applicability
  • New study shows CDK4/6-inhibiting drug palbociclib not only arrests cancer cell division but can also induce cancer cell death in tumors with high level of key protein. Discovery raises prospect of clinical test to identify patients who can gain particular benefit from CDK4/6 inhibitors.

Gordon Freeman, PhD
Eric Winder, MD

Dana Farber In the News

Publications

    Image Alt Text
    Image Alt Text
    Image Alt Text


Content